(Circulation. 2001;103:961.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention
Aggregate Results From 6 Randomized, Controlled Trials
From the Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio.
Correspondence to Eric J. Topol, MD, Department of Cardiology, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Ave, Cleveland, Ohio 44195. E-mail topole{at}ccf.org
Background—Unfractionated heparin has been the primary anticoagulant therapy for percutaneous coronary intervention for >20 years. Despite the availability of rapid "point of care" testing, little clinical data defining the optimal level of anticoagulation are available. Furthermore, recent reports have advocated the use of low-dose heparin regimens in the absence of large-scale, well-conducted studies to support this practice.
Methods and Results—We pooled the data from 6 randomized, controlled trials of novel adjunctive antithrombotic regimens for percutaneous coronary interventions in which unfractionated heparin constituted the control arm. Patients were divided into 25-s intervals of activated clotting times (ACTs), from <275 s to >476 s. In a total of 5216 patients, the incidence of death, myocardial infarction, or any revascularization and major or minor bleeding at 7 days were calculated for each group and compared. An ACT in the range of 350 to 375 s provided the lowest composite ischemic event rate of 6.6%, or a 34% relative risk reduction in 7-day ischemic events compared with rates observed between 171 and 295 s by quartile analysis (P=0.001).
Conclusions—Contrary to recent reports, the optimal suppression of ischemic events with unfractionated heparin therapy in patients undergoing percutaneous coronary intervention demands treatment to ACT levels that are substantially higher than currently appreciated. These data define a goal for heparin dosing within coronary interventions and establish a benchmark of optimal unfractionated heparin therapy against which future trials of novel antithrombotic regimens in percutaneous interventions can be compared.
Key Words: heparin • clinical trials • pharmacology • coagulation
This article has been cited by other articles:
 |
|
 |
|
  I. R. Sheikh, S. H. Ahmed, N. Mori, A. Gupta, M. Mewissen, S. Allaqaband, and T. Bajwa Comparison of Safety and Efficacy of Bivalirudin Versus Unfractionated Heparin in Percutaneous Peripheral Intervention: A Single-Center Experience J. Am. Coll. Cardiol. Intv., September 1, 2009; 2(9): 871 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Kinnaird, R Anderson, J Hill, and M Thomas Bleeding during percutaneous intervention: tailoring the approach to minimise risk Heart, January 1, 2009; 95(1): 15 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Stabile, W. Nammas, L. Salemme, G. Sorropago, A. Cioppa, T. Tesorio, V. Ambrosini, E. Campopiano, G. Popusoi, G. Biondi Zoccai, et al. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: A Randomized Study Comparing Standard Anticoagulation Regimen to Absence of Anticoagulation for Elective Percutaneous Coronary Intervention J. Am. Coll. Cardiol., October 14, 2008; 52(16): 1293 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Dauerman Coronary Intervention Without a Safety Net J. Am. Coll. Cardiol., October 14, 2008; 52(16): 1299 - 1301. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kastrati, F.-J. Neumann, J. Mehilli, R. A. Byrne, R. Iijima, H. J. Buttner, A. A. Khattab, S. Schulz, J. C. Blankenship, J. Pache, et al. Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention N. Engl. J. Med., August 14, 2008; 359(7): 688 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 708S - 775S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Montalescot, M. Cohen, G. Salette, W. J. Desmet, C. Macaya, P. E.G. Aylward, Ph. G. Steg, H. D. White, R. Gallo, S. R. Steinhubl, et al. Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial Eur. Heart J., February 2, 2008; 29(4): 462 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dumaine, M. Borentain, O. Bertel, C. Bode, R. Gallo, H. D. White, J.-P. Collet, S. R. Steinhubl, and G. Montalescot Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials Arch Intern Med, December 10, 2007; 167(22): 2423 - 2430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dobrzycki, P. Kralisz, K. Nowak, P. Prokopczuk, W. Kochman, J. Korecki, B. Poniatowski, J. Zuk, E. Sitniewska, H. Bachorzewska-Gajewska, et al. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals Eur. Heart J., October 2, 2007; 28(20): 2438 - 2448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Tremey, B. Szekely, S. Schlumberger, D. Francois, N. Liu, K. Sievert, and M. Fischler Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron(R) low range activated clotting time (ACT-LR) Br. J. Anaesth., October 1, 2006; 97(4): 453 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gibson, D. A. Morrow, S. A. Murphy, T. M. Palabrica, L. K. Jennings, P. H. Stone, H. H. Lui, T. Bulle, N. Lakkis, R. Kovach, et al. A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT-TIMI-30 Trial J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2364 - 2373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Tadros, K. Broder, and F. Bachour Intracoronary Macrothrombus Formation During Percutaneous Coronary Intervention Despite Optimal Activated Clotting Time Using Bivalirudin: A Case Report Angiology, November 1, 2005; 56(6): 761 - 765. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Wilson, J. Gilbert, M. Harlan, A. Bracey, P. Allison, C. Schooley, and K. Pinto High-dose Intravenous Dalteparin Can be Monitored Effectively Using Standard Coagulation Times Clinical and Applied Thrombosis/Hemostasis, April 1, 2005; 11(2): 127 - 138. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Mehilli, A. Kastrati, H. Schuhlen, A. Dibra, F. Dotzer, N. von Beckerath, H. Bollwein, J. Pache, J. Dirschinger, P. P. Berger, et al. Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel Circulation, December 14, 2004; 110(24): 3627 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Smythe and A. Caffee Anticoagulation Monitoring Journal of Pharmacy Practice, October 1, 2004; 17(5): 317 - 326. [Abstract] [PDF]
|
|
|
|
|
|
M. N. Levine, G. Raskob, R. J. Beyth, C. Kearon, and S. Schulman Hemorrhagic Complications of Anticoagulant Treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 287S - 310S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 609S - 626S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Brener, D. J. Moliterno, A. M. Lincoff, S. R. Steinhubl, K. E. Wolski, and E. J. Topol Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications: Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary Intervention Circulation, August 24, 2004; 110(8): 994 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Montalescot, H R Andersen, D Antoniucci, A Betriu, M J de Boer, L Grip, F J Neumann, and M T Rothman Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction Heart, June 1, 2004; 90(6): e37 - e37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kastrati, J. Mehilli, H. Schuhlen, J. Dirschinger, F. Dotzer, J. M. ten Berg, F.-J. Neumann, H. Bollwein, C. Volmer, M. Gawaz, et al. A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel N. Engl. J. Med., January 15, 2004; 350(3): 232 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Moliterno, J. B. Hermiller, D. J. Kereiakes, E. Yow, R. J. Applegate, G. A. Braden, E. J. Dippel, M. I. Furman, C. L. Grines, N. S. Kleiman, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1132 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lincoff, J. A. Bittl, R. A. Harrington, F. Feit, N. S. Kleiman, J. D. Jackman, I. J. Sarembock, D. J. Cohen, D. Spriggs, R. Ebrahimi, et al. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial JAMA, February 19, 2003; 289(7): 853 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Tolleson, J. C. O'Shea, J. A. Bittl, W. B. Hillegass, K. A. Williams, G. Levine, R. A. Harrington, and J. E. Tcheng Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial J. Am. Coll. Cardiol., February 5, 2003; 41(3): 386 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Marmur, S. X. Anand, R. S. Bagga, J. Fareed, C.-M. Pan, S. K. Sharma, and M. F. Richard The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration J. Am. Coll. Cardiol., February 5, 2003; 41(3): 394 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.e. Choussat, G. Montalescot, J. P. Collet, E. Vicaut, A. Ankri, V. Gallois, G.e. Drobinski, I. Sotirov, and D. Thomas A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention J. Am. Coll. Cardiol., December 4, 2002; 40(11): 1943 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Niccoli and A P Banning Heparin dose during percutaneous coronary intervention: how low dare we go? Heart, October 1, 2002; 88(4): 331 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D J Blackman, N R Clarke, W P Orr, E Wilkinson, A Beswick, D Coppock, D C Sprigings, and A P Banning Day-case transfer for percutaneous coronary intervention with adjunctive abciximab in acute coronary syndromes Heart, April 1, 2002; 87(4): 375 - 376. [Full Text] [PDF]
|
|
|
|
|
|
J. I. Weitz and H. R. Buller Direct Thrombin Inhibitors in Acute Coronary Syndromes: Present and Future Circulation, February 26, 2002; 105(8): 1004 - 1011. [Full Text] [PDF]
|
|
|
|
|
|
H. Mehta and B. J. Meyer r-Hirudin for percutaneous coronary interventions--time to reconsider? Eur. Heart J., January 2, 2002; 23(2): 95 - 97. [Full Text] [PDF]
|
|
|
|
|
|
G. Helft, F. Beygui, C. le Feuvre, J. P. Metzger, D. P. Chew, D. L. Bhatt, A. M. Lincoff, D. J. Moliterno, S. J. Brener, K. E. Wolski, et al. Defining the Optimal Activated Clotting Times During Percutaneous Coronary Intervention: Aggregate Results From 6 Randomized, Controlled Trials Response Circulation, November 27, 2001; 104 (22): e124 - e124. [Full Text] [PDF]
|
|
|
|
|
|
C. G. Hanratty, M. Ward, D. P. Chew, D. L. Bhatt, A. M. Lincoff, D. J. Moliterno, S. J. Brener, K. E. Wolski, and E. J. Topol Optimal Activated Clotting Time During Percutaneous Coronary Intervention Response Circulation, October 9, 2001; 104 (15): e83 - e84. [Full Text] [PDF]
|
|